Vimseltinib
Romvimza · CSF1R tyrosine kinase inhibitor
A clean-kidney targeted TKI — watch the CPK, not the nephron.
Ojjaara · MOME
JAK/ACVR1 inhibitor · approved 2023 · 7 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A JAK1/2 plus ACVR1 inhibitor for anemic myelofibrosis whose characteristic renal signal is a frequent, low-grade creatinine rise without true GFR loss.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
17–29% range across studies
Treatment-emergent 'nephropathy' — a predominantly low-grade, isolated serum-creatinine rise — is now a recognized and frequent momelotinib signal, reported in ~17-29% across real-world cohorts (~29% in first-line real-world use; ~17% CTCAE grade 1-2 creatinine increase in a retrospective real-world cohort). Momelotinib pharmacokinetics are unchanged across renal impairment, arguing the creatinine rise reflects altered tubular handling rather than a true GFR fall (a pseudo-AKI). Tumor-lysis at initiation in high-burden disease remains a separate, indirect risk.Source: Tefferi et al., Am J Hematol 2026
Any tumor-lysis risk is early, but otherwise there is no defined renal onset.
Distilled from: “Any tumor-lysis risk is early; otherwise no defined renal onset.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Tap a signature to trace where it strikes the nephron.
Representative incidence · 17–29% range across studies
Pseudo-AKI strikes: Proximal Tubule.
Pseudo-AKI
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Oral inhibitor of JAK1/JAK2 and ACVR1 (ALK2). ACVR1 inhibition lowers hepcidin via the BMP6/ACVR1/SMAD axis, increasing iron availability and improving anemia — distinguishing it from other JAK inhibitors. Approved for intermediate/high-risk myelofibrosis with anemia.
7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 1,481 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
230 of 1,481 reports
Reported with hospitalization
349 of 1,481 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Momelotinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Romvimza · CSF1R tyrosine kinase inhibitor
A clean-kidney targeted TKI — watch the CPK, not the nephron.
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Bosulif · BCR-ABL TKI
Reversible eGFR decline.
Zykadia · ALK TKI
GI-driven prerenal AKI.
Gavreto · RET inhibitor
Hypertension; rare AKI.
Voranigo · Mutant IDH1/2 inhibitor
A brain-penetrant IDH inhibitor whose kidney footprint is a benign creatinine bump, not true AKI.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.